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unravelling genetic and environmental architectures of severe
mental disorders
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CS Hansen1,4, JJ McGrath1,2,7,8, TD Als1,5, JI Goldstein9,10,11, BM Neale9,10,11, MJ Daly9,10,11, DM Hougaard1,4,16, O Mors1,12,16,
M Nordentoft1,13,16, AD Børglum1,5,16, T Werge1,14,16 and PB Mortensen1,2,3,5,16
The Integrative Psychiatric Research (iPSYCH) consortium has established a large Danish population-based Case–Cohort sample
(iPSYCH2012) aimed at unravelling the genetic and environmental architecture of severe mental disorders. The iPSYCH2012 sample
is nested within the entire Danish population born between 1981 and 2005, including 1 472 762 persons. This paper introduces the
iPSYCH2012 sample and outlines key future research directions. Cases were identiﬁed as persons with schizophrenia (N= 3540),
autism (N= 16 146), attention-deﬁcit/hyperactivity disorder (N= 18 726) and affective disorder (N= 26 380), of which 1928 had
bipolar affective disorder. Controls were randomly sampled individuals (N= 30 000). Within the sample of 86 189 individuals, a total
of 57 377 individuals had at least one major mental disorder. DNA was extracted from the neonatal dried blood spot samples
obtained from the Danish Neonatal Screening Biobank and genotyped using the Illumina PsychChip. Genotyping was successful for
90% of the sample. The assessments of exome sequencing, methylation proﬁling, metabolome proﬁling, vitamin-D, inﬂammatory
and neurotrophic factors are in progress. For each individual, the iPSYCH2012 sample also includes longitudinal information on
health, prescribed medicine, social and socioeconomic information, and analogous information among relatives. To the best of our
knowledge, the iPSYCH2012 sample is the largest and most comprehensive data source for the combined study of genetic and
environmental aetiologies of severe mental disorders.
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INTRODUCTION
The fundamental nature of mental disorders remains poorly
understood, but genetic factors have an important role.1–7
Considerable progress in psychiatric genetics has been made in
recent years, based on large samples and international collabora-
tions, for example, through the pivotal efforts of the Psychiatric
Genomics Consortium.8 We can expect that larger samples will
reveal new insights to common and rare variants underpinning
mental disorders.9
Many environmental factors inﬂuencing pre- and postnatal
development are associated with schizophrenia, bipolar affective
disorder, autism and attention-deﬁcit/hyperactivity disorder, and
furthermore, adverse life circumstances increase the risk of mental
disorders. Gene–environment synergism contributes to the
aetiology of these disorders, but suitable datasets to explore this
important ﬁeld of research have been lacking. To understand the
impact of genes and environments over the life course, large and
truly population-based longitudinal cohort studies are
required.10,11
As part of the Lundbeck Foundation Initiative for Integrative
Psychiatric Research (iPSYCH: http://iPSYCH.au.dk/), a large case–
cohort study has commenced. In most countries, it would not be
logistically feasible to compile large, representative population-based
samples. In Denmark, the existence of (a) a universal public health
care system free of charge, (b) several national longitudinal registers
and (c) strict ethical and data protection legislation required to
safeguard the privacy of study participants, has provided a
remarkable research platform.12 Recent technological developments
and a new legal framework for use of bio-banked material for
research have created similar possibilities for genetic research.
The vision of iPSYCH was to leverage these combined resources,
considering the entire national cohort as our study population.
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We utilized information on individuals with a diagnosis of selected
mental disorders (N= 57 377) and a randomly sampled cohort13,14
of the general population (N= 30 000). The sample is known as the
iPSYCH Danish case-cohort study (iPSYCH2012). We used neonatal
dried blood spots from the Danish Neonatal Screening Biobank to
investigate detailed genetic and biomarker information, some of
which are markers of environmental exposures. The rich Danish
population-based registers were used to add information on all
individuals and all their relatives. Thus, we created a comprehen-
sive data source for the combined study of genetic and
environmental aetiologies of severe mental disorders. Within the
iPSYCH2012 sample, currently around 77 500 individuals have
been array genotyped and around 20 000 have been whole
exome sequenced. Ten thousand samples have been analysed for
ranges of cytokines and neurotrophic factors. Epigenetic and
metabolome data from several thousand samples are emerging.
For the entire sample and their relatives, detailed longitudinal
information related to health, prescribed medicine, social and
socioeconomic information exists. This study provides a general
overview of the sample design and outlines future research.
THE OVERALL DESIGN
Individuals diagnosed with schizophrenia, mood disorders, bipolar
affective disorder, autism and attention-deﬁcit/hyperactivity dis-
order were identiﬁed through linkage between Danish
population-based registers along with a random sample of the
same population that supplied the cases.15 Dried blood spots for
virtually all individuals were retrieved from the Danish Neonatal
Screening Biobank and processed for genotyping. The design
includes the ability to efﬁciently analyse prospectively collected
cohort data within the iPSYCH case–cohort sample.15 This
particular design provides several advantages: As the cohort is
randomly selected from the entire population, we are able to
generate unbiased absolute risks and incidence rates and to
estimate the effect sizes of genetic markers on risk of mental
disorders, which is representative of the entire Danish population.
To date, most genetic and epidemiological studies are based on
convenient case-control samples, which are prone to biases.15,16
The iPSYCH2012 sample was preceded by four smaller Danish
samples,17–24 all aiming to investigate the potential interplay
between genes and the environment. Collectively, these
forerunners informed on the best possible study design to use
in the iPSYCH2012 sample (Supplementary Text 1). The following
three paragraphs describe the resources and methods used to
identify individuals included in the iPSYCH2012 sample.
SELECTING THE STUDY BASE
The Danish Civil Registration System was established in 1968,25
where all people alive and living in Denmark were registered. It
includes information on the unique personal identiﬁcation
number, sex, date and place of birth, parents’ identiﬁers and
continuously updated information on emigration and death. The
personal identiﬁcation number is used in all national registers
enabling accurate linkage within and between registers. The study
base included all singleton births with known mothers born
between 1 of May 1981 and 31 of December 2005, who were alive
and resided in Denmark at their ﬁrst birthday (N= 1 472 762
persons). Selecting births in this period ensures individual samples
to be retrieved in the Danish Neonatal Screening Biobank and
reasonable distribution of cases and cohort members for all birth
years. All residents are registered in the Danish Civil Registration
System irrespective of health, income, receipt of social beneﬁts,
employment and other socioeconomic characteristics.26
DIAGNOSES OF MENTAL DISORDERS
Persons within the study base were linked via their personal
identiﬁer to the Danish Psychiatric Central Research Register27 to
obtain information on mental disorders. The Danish Psychiatric
Central Research Register was computerized in 1969 and contains
data on all admissions to Danish psychiatric in-patient facilities.
Information on outpatient visits was included from 1995 onwards.
From 1994 onwards, the International Classiﬁcation of Diseases,
10th revision, Diagnostic Criteria for Research was used for
diagnostic classiﬁcation.28 All persons within the study base, who
had a diagnosis of schizophrenia, bipolar disorder, affective
disorder, autism and attention-deﬁcit/hyperactivity disorder were
included (Table 1). At the time of linkage, the Danish Psychiatric
Central Research Register contained all psychiatric contacts until
31 December 2012. Table 1 summarizes the number of individuals
across the diagnostic groups.
Table 1. Number of persons included in iPSYCHs population-based sample of the Danish population born 1981–2005
Number of persons
Group membershipa ICD10 diagnosesb Follow-up
period
Initial
Sample
Blood spots available in Biobank
and sent to Broad
Passed Sample
QC
Schizophreniac F20 2009–2012 3540 2830 2738
Bipolar disorder F30–F31 1994–2012 1928 1488 1452
Affective disorder F30–F39 1994–2012 26 380 23 532 22 809
Autism F84.0, F84.1, F84.5, F84.8 or F84.9 1994–2012 16 146 15 418 14 812
ADHD F90.0 1994–2012 18 726 17 835 17 249
Any case All ICD codes listed above 57 377 52 867 51 101
Population-based cohort Random sampling, i.e., disregarding
any diagnostic information
30 000 28 650 27 605
Total number of persons 86 189 80 422 77 639
Abbreviations: ADHD, attention-deﬁcit/hyperactivity disorder; ICD-10, International Classiﬁcation of Diseases, 10th revision; iPSYCH, Integrative Psychiatric
Research; QC, quality control. aGroups are not mutually exclusive. bInitial ICD10 diagnosis used to select case groups. Identiﬁcation was performed through
linkage to the Danish Psychiatric Central Research Register. At the time of linkage, the register contained all contacts up until 31/12/2012. cInclude all persons
ﬁrst diagnosed with schizophrenia during the period from 1 January 2009 to 31 December 2012 and persons ﬁrst diagnosed with schizophrenia before 1
January 2009 that were not already genotyped (N= 923). A total of 1887 persons ﬁrst diagnosed with schizophrenia before 1 January 2009 were previously
genotyped (see Supplementary Text 1).
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SELECTING THE POPULATION-BASED COHORT
Among the 1 472 762 persons included in the study base, a total
of 30 000 persons were chosen uniformly at random (Table 1)
corresponding to 2.04% of the study base ( = 30 000/1 472 762).
As the cohort members were chosen randomly, some cohort
members may also have the disorders of interest.13,14 Thus,
the cohort selected is representative of the entire Danish
population born in the same period.26 In addition, the cohort
members are at risk of developing the disorder of interest
during follow-up, whereas controls are typically conditioned to
be healthy until the study ends.29 We have thereby identiﬁed
the individuals to be included in the iPSYCH2012 sample.
Next, we describe the enrichment with genetic and other
biomarker data.
THE DANISH NEONATAL SCREENING BIOBANK
Blood spots for individuals included in the iPSYCH2012 sample were
retrieved from the Danish Neonatal Screening Biobank within the
Danish National Biobank.30 This facility stores dried blood spot
samples taken from practically all neonates born in Denmark since 1
May 1981 and stored at −20 °C. These samples were collected
primarily for diagnosis of congenital disorders. The samples are
stored for follow-up diagnostics, screening, quality control and
research. At time of blood sampling (4–7 days after birth), parents are
informed in writing about the neonatal screening and that the blood
spots are stored in the Danish Neonatal Screening Biobank and can
be used for research, pending approval from relevant authorities. The
parents are also informed about how to prevent or withdraw the
sample from inclusion in research studies.
Figure 1. The selected samples were correlated with their DNSB identiﬁers and entered into an in-house developed selection database (Step 1
and 2). Sample identities were then validated and assigned a pseudonymized unique ID (Step 3) before cutting two discs of 3.2 mm of dried
blood into a 96-well PCR plate (Step 4). Proteins were washed of the blood spots and stored at − 80 °C before DNA was extracted using
Extract-N-Amp Blood PCR Kit (Sigma-Aldrich, St Louis, MO, USA) (Step 5). DNA was ampliﬁed in triplicates using REPLI-g (Qiagen, Hilden,
Germany) and combined to a single sample (Step 6). Finally, concentrations were quantiﬁed using Quant-iT picogreen (Invitrogen, Carlsbad,
CA, USA) (Step 7) and a genetic ﬁngerprint established using the iPLEX pro Sample ID panel (Agena Bioscience, Hamburg, Germany) (Step 8)
before aliquoting a fraction of the sample for genotyping (Step 9).
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Genotyping was based on two blood spot punches of 3.2 mm,
equivalent to 6 μl of whole blood.30 Biological components are
generally very well preserved in neonatal dried blood spot
samples, in particular if the samples are stored at − 20 ⁰C.
However, it may be challenging to analyse the samples due to
the very limited amount of biological material available, the nature
of dried whole blood on ﬁlter paper and decades of storage. In
particular, the determination of concentration of biomarkers in
dried blood spots is less precise than in serum. This calculation is
based on the assumption that one punch 3.2 mm in diameter is
equivalent to 3 μl of whole blood, which only applies if the ﬁlter
paper is fully and evenly saturated. Moreover, measurements are
performed on whole blood containing various cell types that may
have an inﬂuence on the concentration of certain components.
The hematocrit, which is usually unknown, is also an important
factor for blood components that do not re-distribute into red
blood cells. Special high sensitive assays may be required and
multi-analyte measurements are preferred to get as much
information of the limited samples as possible. The neonatal
dried blood spots is suitable for next generation sequencing,31
DNA methylation proﬁling,32 metabolome proﬁling, vitamin D,33
multiplex measurements of cytokines,34 antibodies to infectious
agents19 and whole transcriptome analysis through microarray35
and RNA-seq.36 Importantly, these measurements are made in
samples drawn few days after birth, meaning that case-control
differences cannot be ascribed to disease-related confounders as
medication, alcohol or substance use, smoking or the disease state
itself.
Systematic comparisons of genomic DNA versus whole-
genome-ampliﬁed DNA37 reveals increased signal noise. Although
this has very little impact on genotype calls, it is problematic for
Copy Number Variation detection algorithms such as PennCNV.38
Efforts within the iPSYCH community are making progress towards
solving the noise issues. Technical reproductions using RNA
microarrays reported in Grauholm et al.35 indicated high
reproducibility, independently of spot size, and indicated that
the critical factor is storage conditions rather than storage length.
Ho et al.39 found differences between cerebral palsy cases and
matched controls using dried blood spots from the Michigan
neonatal screening. Combined these reports strongly indicate that
it is possible to do meaningful transcriptome experiments despite
prolonged storage at perceived sub-optimal conditions.
Preparation of samples for genotyping and sequencing from
the Danish neonatal screening biobank DNA was extracted and
whole genome ampliﬁed at the Statens Serum Institut following
previously established procedures.40,41 The sample ﬂow is
described in Figure 1.
ARRAY GENOTYPING AND QUALITY CONTROL
Samples were processed at the Broad Institute (Boston, MA, USA)
using the Inﬁnium PsychChip v1.0 array (Illumina, San Diego, CA,
USA) in accordance with the manufacturer’s instructions.42
Genotyping was conducted in 25 waves. Variant calls were trained
using GenTrain2 (Illumina) on the ﬁrst wave (4146 samples) using
the PsychChip 15048346 B manifest and GenomeStudio version
v2011.1. Following autoclustering, loci were manually curated if
they had a call frequency below 90%, GenTrain scores below 0.5 or
cluster separation below 0.2. During this processing, 3890 loci
were excluded and 928 were manually modiﬁed. The resulting
GenTrain was used to produce GenCall variant calls used for
sample level quality control of the entire cohort.43 Samples with
call rates below 95% (N= 2270) were designated to fail sample
quality control (QC). Sex was inferred using heterozygosity on
chromosome X; below 20% in males; above 20% in females. Sex
obtained from genotyping was compared to the sex recorded in
the Danish Civil Registration System and mismatches were
excluded. It is extremely unlikely to observe errors in recorded
sex in the Danish Civil Registration System.26 About 0.25%
(N= 224) of the sample did not match the expected sex. Half of
the failures (N= 119) were due to abnormal structural variation on
chromosome X (aneuploidy and loss of heterozygosity). The other
half were due to sample mix-ups (N= 103). In this study we
describe the sample QC only and not the subsequent single-
nucleotide polymorphism QC, which vary between studies.
PROBE REMAPPING
All probe sequences were queried against an HG19 database
using a nucleotide version of the Basic Local Alignment Search
Tool. The Basic Local Alignment Search Tool results were
compared with the original array manifest, an Illumina update to
the array manifest, and the Broad Institute updates to the
manifest. The genomic coordinates matched between the Basic
Local Alignment Search Tool results and the existing manifests for
95.12% of probes. 2.23% of probes were updated based on the
new Basic Local Alignment Search Tool results. 2.11% retained
their original mapping. The remaining 0.54% were split between
the Broad Institute reference and the Illumina update or the probe
was removed from the data set (Supplementary Table 1).
IMPROVING VARIANT CALLS
GenCall,43 Birdseed44 and zCall45 were used supplementary to
improve variant calls. GenCall and Birdseed are genotype calling
algorithms best suited for common variants, while zCall is a post-
processing step for GenCall to improve genotype calling for rare
variants. Approximately half of the probes on the array are
common variants (minor allele frequency⩾ 0.05), while the other
half are rare variants (minor allele frequencyo0.05). A large
subgroup of the rare variants are non-polymorphic within the
cohort. A consensus genotype call was made from the three
calling algorithms (Supplementary Text 2) using PLINK.46,47
ETHICAL FRAMEWORK
The Danish Scientiﬁc Ethics Committee, the Danish Health Data
Authority, the Danish data protection agency and the Danish
Neonatal Screening Biobank Steering Committee approved this
study. This is in keeping with the strict ethical framework and the
Danish legislation protecting the use of these samples.30,48
Permission has been granted to study genetic and environmental
factors for the development and prognosis of mental disorders. To
unravel the foundation of severe mental disorders, it is central that
this rich data source is accessible to the international research
community to the largest extent possible. It is also paramount to
protect the privacy of the individuals included in the study. Owing
to the sensitive nature of these data, individual level data can be
accessed only through secure servers where download of
individual level information is prohibited.49 iPSYCH encourage
national and international collaboration. For details, please contact
Professor Preben Bo Mortensen, Scientiﬁc Director of iPSYCH.
BASELINE CHARACTERISTICS
Table 2 shows baseline characteristics of the 86 189 individuals
included in the iPSYCH2012 sample. Among these individuals,
77 639 (90%) passed sample QC. In the cohort group, males
constituted 51% in both the initial and in the QC’ed sample. The
following numbers refer to the initial sample: Overall, 26 380
individuals were included due to suffering from an affective
disorder. Among individuals with affective disorder, 543 indivi-
duals were incidentally also among the cohort members, that is,
the 2.03% random sample of the study base. Overall, 28 812
(96.04%) of the 30 000 cohort members had none of the 5
psychiatric diagnoses until 2012. A total of 49 737 (86.68%) cases
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and 25 159 (83.86%) cohort members were native Danes. The
largest second-generation immigrant group was persons having
one or both parents born in Europe followed by one or both
parents born in Scandinavia.
Comparing the percentage of cases included in the initial
sample with the percentage of cases passing the QC revealed no
systematic deviations across selected baseline characteristics
(Table 2). Comparing the percentage of cohort members included
Table 2. Baseline characteristics of the iPSYCH2012 case–cohort
Initial sample, N= 86 189 Passed sample QC, N= 77 639
Casesa, N= 57 377 Cohorta, N=30 000 Casesa, N= 51 101 Cohorta, N= 27 605
Sex
Male 32 243 (56.19%) 15 308 (51.03%) 29 048 (56.84%) 14 090 (51.04%)
Female 25 134 (43.81%) 14 692 (48.97%) 22 053 (43.16%) 13 515 (48.96%)
Year of birth
1981–1985 11 909 (20.76%) 4858 (16.19%) 9409 (18.41%) 4175 (15.12%)
1986–1990 14 506 (25.28%) 5838 (19.46%) 12 766 (24.98%) 5361 (19.42%)
1991–1995 14 521 (25.29%) 6597 (21.99%) 13 508 (26.43%) 6190 (22.42%)
1996–2000 10 306 (17.96%) 6461 (21.54%) 9796 (19.17%) 6182 (22.39%)
2001–2005 6144 (10.71%) 6246 (20.82%) 5622 (11.00%) 5697 (20.64%)
Diagnosisb
Schizophrenia 3540 (6.17%) 90 (0.30%) 2738 (5.36%) 65 (0.24%)
Bipolar affective disorder 1928 (3.36%) 42 (0.14%) 1452 (2.84%) 31 (0.11%)
Affective disorder 26 380 (45.98%) 543 (1.81%) 22 809 (44.64%) 467 (1.69%)
Autism 16 146 (28.14%) 324 (1.08%) 14 812 (28.99%) 309 (1.12%)
ADHD 18 726 (32.64%) 387 (1.29%) 17 249 (33.75%) 360 (1.30%)
None of the above 0 (0.00%) 28812 (96.04%) 0 (0.00%) 26 538 (96.13%)
Parental originc
Denmark 49 737 (86.68%) 25 159 (83.86%) 44 284 (86.66%) 23 213 (84.09%)
Africa 619 (1.08%) 446 (1.49%) 566 (1.11%) 400 (1.45%)
America 472 (0.82%) 228 (0.76%) 419 (0.82%) 204 (0.74%)
Asia 731 (1.27%) 672 (2.24%) 648 (1.27%) 616 (2.23%)
Australia 51 (0.09%) 29 (0.10%) 47 (0.09%) 29 (0.11%)
Europe excl Scandinavia 2508 (4.37%) 1557 (5.19%) 2228 (4.36%) 1406 (5.09%)
Greenland 341 (0.59%) 162 (0.54%) 306 (0.60%) 148 (0.54%)
Middle East 666 (1.16%) 625 (2.08%) 604 (1.18%) 568 (2.06%)
Scandinavia excl Denmark 1168 (2.04%) 600 (2.00%) 1047 (2.05%) 549 (1.99%)
Mixed parentage 221 (0.39%) 166 (0.55%) 190 (0.37%) 146 (0.53%)
Unknown 863 (1.50%) 356 (1.19%) 762 (1.49%) 326 (1.18%)
Birth weight
o1500 g 475 (0.83%) 145 (0.48%) 381 (0.75%) 125 (0.45%)
1500–2499 g 2613 (4.55%) 924 (3.08%) 2197 (4.30%) 808 (2.93%)
2500–3499 g 26 735 (46.60%) 13 302 (44.34%) 23 758 (46.49%) 12 245 (44.36%)
3500–4499 g 25 500 (44.44%) 14 491 (48.30%) 22 918 (44.85%) 13 425 (48.63%)
⩾ 4500 g 1739 (3.03%) 954 (3.18%) 1600 (3.13%) 883 (3.20%)
Missing information 315 (0.55%) 184 (0.61%) 247 (0.48%) 119 (0.43%)
Gestational age
o35 weeks 1342 (2.34%) 458 (1.53%) 1105 (2.16%) 397 (1.44%)
35–36 weeks 1907 (3.32%) 857 (2.86%) 1648 (3.22%) 776 (2.81%)
37–38 weeks 8650 (15.08%) 4305 (14.35%) 7754 (15.17%) 3998 (14.48%)
39–40 weeks 29 768 (51.88%) 15 835 (52.78%) 26 642 (52.14%) 14 640 (53.03%)
⩾ 41 weeks 14 995 (26.13%) 8239 (27.46%) 13 440 (26.30%) 7594 (27.51%)
Missing information 715 (1.25%) 306 (1.02%) 512 (1.00%) 200 (0.72%)
Apgar score (5 min)
1–5 238 (0.41%) 113 (0.38%) 204 (0.40%) 107 (0.39%)
6–7 617 (1.08%) 224 (0.75%) 523 (1.02%) 199 (0.72%)
8–9 3460 (6.03%) 1712 (5.71%) 3083 (6.03%) 1573 (5.70%)
10 52 284 (91.12%) 27 590 (91.97%) 46 666 (91.32%) 25 445 (92.18%)
Missing information 778 (1.36%) 361 (1.20%) 625 (1.22%) 281 (1.02%)
Abbreviations: ADHD, attention-deﬁcit/hyperactivity disorder; iPSYCH, Integrative Psychiatric Research; QC, quality control. aPersons who were both selected
as cases and cohortees constitute 1188 persons in the initial sample and 1067 persons in the QC’ed sample. These individuals were counted both in the case
and cohort group. bPsychiatric diagnosis at time of selection as described in the method section. Some persons may both be selected in the case and cohort
group, have more than one diagnoses and may later have additional diagnoses. cPersons with both parents born in Denmark were classiﬁed as having Danish
parental origin. Persons having a Danish-born parent and a foreign born parent were classiﬁed as the foreign-born parents region of birth. Persons having two
foreign-born parents born in the same region were classiﬁed with that region. Persons having two foreign-born parents born in different regions were
classiﬁed as mixed.
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in the initial sample with the percentage of cohort members
passing QC also revealed no systematic deviations across baseline
characteristics.
VISUALIZATION OF GENETIC DATA BY FOREIGN PARENTAL
ORIGIN
To visualize population substructure for the genetic data, a
principle component analysis was conducted (Supplementary Text 3).
There was a clear correspondence between the ﬁrst two principal
components based on the genome-wide single-nucleotide poly-
morphism genotypic data and parental country of birth as
registered in the Danish Civil Registration System (Figure 2).
Individuals born in Denmark to parents born in other Scandina-
vian countries clustered together with Danish-born individuals
with Danish-born parents, as expected. Within each foreign
parental region of birth, individuals with two foreign parents
were as anticipated more genetically divergent compared to those
having only one foreign-born parent. This ﬁnding provides strong
evidence of internal validity for processing of individual samples
and the ability to link to information in the rich Danish registers on
an individual level.
PERSPECTIVES
The large iPSYCH2012 sample will provide a solid foundation for a
range of studies in decades ahead. We have completed
genotyping and plans are advanced for a range of other analyses,
including an update and major expansion with cases diagnosed
since 2012, as well as including new diagnostic case groups. The
sample is thus not only a rich database for research in the current
version - it also constitutes a logistic and organizational framework
for future studies, although each new study will require relevant
ethical permissions. Most other genetic studies are based on
samples of convenience rather than utilizing true population-
based samples. To our knowledge, no large-scale population-
based sample with genome-wide association study data exists
elsewhere. In particular, we are conﬁdent that the iPSYCH2012
sample provides an important resource to explore novel ways to
combine genetic, phenotypic and environmental factors. Pheno-
typic and environmental factors are readily available through
record linkage between the numerous Danish registers or assayed
from neonatal dried blood spots.
Access to high-quality, population-based person-linked registers
has enabled major contributions to psychiatric epidemiology. For
example, researchers have documented key risk factors within
psychiatric epidemiology, for example, urban birth,50–54 paternal
age,55–57 psychiatric family history,58,59 life-time risk,60
infections,17,19,20 neonatal vitamin D deﬁciency,61 socio-economic
adversity,62 treatment resistant schizophrenia,63 pharmacological
treatment,64 suicide65 and excess mortality.66 Key features such as
the avoidance of selection bias and control of multiple
confounders have been important aspects of these studies.
However, genetic studies have traditionally not had access to
population-based samples, with cases often recruited from
multiplex families, or convenient samples of prevalent cases in
contact with mental health services. The iPSYCH2012 sample
includes a large representative sample of severe mental disorders
from a representative sampling frame. The possibility to link the
iPSYCH2012 sample to the comprehensive and high quality
Danish population-based registers offers researchers unique
possibilities to study the interplay between the genetic factors,
and variables from the environment, and variables related to
health,27,67–69 mortality, income and social and socioeconomic
characteristics.70–72 Genetic association studies are by default
observational studies, subject to many of the same sources of bias
and confounding as other epidemiological studies.16 Therefore,
we believe our samples can assist the assessment of the potential
impact of such biases and especially lack thereof, and point
toward new avenues of research. For example, it has been shown
that the genetic associations with schizophrenia identiﬁed in the
seminal Psychiatric Genomics Consortium paper3 were stronger in
Figure 2. Scatterplot of the ﬁrst two principal components colored according to parental region of birth. Big circles indicate mean values for
the given parental group. Crosses indicates both parent born abroad within the region indicated by the color. Absence of cross indicate one
Danish born parent and one parent born in the region indicated by the color. Persons with unknown information on parental region of birth
(N= 1088) and mixed parentage are not shown (N= 366).
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more chronic cases than in ﬁrst episode cases.73 This may suggest
that, in future studies, the genetic architecture of schizophrenia
could perhaps be reﬁned to identify genes particularly associated
with the risk of developing disease, and genes particularly
predicting a chronic course, something that could have important
preventive and clinical implications. Such future studies will
beneﬁt from the continued dialogue between epidemiological
studies as iPSYCH and the large-scale studies available only
through collaboration in international consortia.
The iPSYCH2012 sample will be able to leverage single-
nucleotide polymorphism -derived, genome-wide metrics such
as disease-speciﬁc polygenic risk scores.74–76 These provide a
continuous measure of liability (rather than a categorical measure
of family history), which will greatly enhance our ability to
combine genetic, environmental and phenotypic data in disease
prediction. We have found higher polygenic loading for schizo-
phrenia in both cases and controls with family histories of mental
disorders.77 Also 48% of the effect associated with family history of
psychoses was mediated through the polygenic risk score for
schizophrenia.78 To further explore the association between the
risk of schizophrenia and the polygenetic risk score for schizo-
phrenia, we have investigated the interplay with infections,79
treatment resistant schizophrenia,80 chronicity of schizophrenia,73
and mortality and suicidal behaviour.81
Since the initiation of the iPSYCH2012 sample, other related
Danish projects have built on the same framework as that used
within iPSYCH, for example, anorexia (5703 cases), obsessive-
compulsive disorder (7747 cases), conduct disorder (4205 cases),
hyperkinetic conduct disorder (3690 cases) and 1546 twin pairs. All
samples gain power in utilizing cohort members within the
iPSYCH2012 sample, while also contributing to the unique
possibilities of the iPSYCH2012 sample.
STRENGTHS AND LIMITATIONS
Identiﬁcation of cases within the iPSYCH2012 sample is based on
contacts to in- and out-patient psychiatric departments and visits
to psychiatric emergency care units in a nation where treatment is
provided through the government healthcare system free of
charge, and where no private psychiatric hospitals exist. Financial
factors are thus less likely to inﬂuence pathways to healthcare in
Denmark compared to many other nations.82 Unlike samples of
convenience, the iPSYCH2012 sample is representative of the
Danish population irrespectively of (a) recall bias, (b) emigration or
death before sampling, (c) institutional care, (d) imprisonment, (e)
being homeless, (f) health and (g) socioeconomic status.26 In
contrast to most genetic studies, the iPSYCH2012 sample also
provides the unique possibility to explore the potential impact of
the longitudinal trajectory on causes and outcomes of mental
disorders.
Register-based studies like the current study cannot identify
persons with untreated disorders or disorders treated in primary
health care only. Most cases with mild to moderate mental
disorders, for example, mild or moderate depression and anxiety
disorders are thus not registered in the Danish Psychiatric Central
Research Register.27 The major strength of the iPSYCH2012 sample
approach is the comprehensive clinical assessment of all mental
disorders treated in secondary healthcare in a nationwide
population. Validation of the Clinician-derived key diagnoses
(schizophrenia, single depressive episode, affective disorder,
attention-deﬁcit/hyperactivity disorder and autism) has been
carried out with good results.83–88
Limitations include that, from an ethical point of view, we are
not allowed to re-contact individuals for any reason. At present,
it is also unclear to which extend it will be possible to enrich
the iPSYCH2012 sample with information from cohorts including
more detailed information on study participants (for example,
see refs 89–92).
We believe that the iPSYCH2012 sample will aid in accelerating
psychiatric research in preventing and treating severe mental
disorders for the beneﬁt of patients, their families and friends, and
the society.
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